// App-Quantinova.ai

: OR13-4 Safety Profile of Asfotase Alfa Treatment of Patients with Hypophosphatasia: A Pooled Analysis

Researchers

Presenter

  • Michael Whyte

Principal Investigators

  • Nick Bishop

  • Jawad Hasan

  • Christine Hofmann

  • Wolfgang Hogler

  • Cheryl Rockman-Greenberg

  • Veruska Sena

  • Shanggen Zhou

  • Priya Kishnani

Medical Centers

  • Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, Saint Louis, MO, United States

  • Sheffield Children's Hospital, Sheffield, United Kingdom

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Childrens Hospital, University of Wuerzburg, Wuerzburg, Germany

  • Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, , Austria

  • University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine, and Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada

  • Covance Inc, Princeton, New Jersey, United States

  • Pediatrics, Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States

Locations

  • United States

  • United Kingdom

  • Germany

  • Austria

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Nephrology

  • Genetic Disorder

  • Cardiovascular (CVS)

  • Infectious Diseases (ID)

Disease

  • Cardiac arrest

  • Hypophosphatasia

  • Craniosynostosis

  • Nephrolithiasis, calcium oxalate

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Strensiq

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Alexion Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved